Development of a 177 Lu-Labeled Glypican-3-Targeted Antibody Radiopharmaceutical for Adjuvant Radionuclide Therapy Following Hepatocellular Carcinoma Resection

Cancer Biotherapy and Radiopharmaceuticals · Published 2026-07-22 · DOI 10.1177/10849785261458520

Authors (1)

Ke Fang

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year

2026

Citation

Fang, K. (2026). Development of a 177 Lu-Labeled Glypican-3-Targeted Antibody Radiopharmaceutical for Adjuvant Radionuclide Therapy Following Hepatocellular Carcinoma Resection. Cancer Biotherapy and Radiopharmaceuticals. https://doi.org/10.1177/10849785261458520

Related articles

• Boronophenylalanine-Mediated Boron Neutron Capture Therapy Confers Selective Killing of Cervical Cancer by Exploiting DNA Repair Deficiency · Cancer Biotherapy and Radiopharmaceuticals · 2026 · Same journal
• Neural Decoding of Ultrasound-Modulated Pain States via Deep Learning: Insights from Functional Magnetic Resonance Imaging Data · Cancer Biotherapy and Radiopharmaceuticals · 2026 · Same journal
• Prognostic Factor Analysis and Nomogram Development in Castration-Resistant Prostate Cancer with Visceral Metastases for Future Radionuclide Therapy Selection · Cancer Biotherapy and Radiopharmaceuticals · 2026 · Same journal
• Mapping the Intersection of Traditional Chinese Medicine and Ultrasound Therapies in Tumor Microenvironment Research (2014–2024): A Knowledge Atlas Study · Cancer Biotherapy and Radiopharmaceuticals · 2026 · Same journal
• CavitoMod-UTMDNet: A Mechanistic Cavitation–Diffusion Framework for Ultrasound-Targeted Microbubble Destruction–Enhanced Liposomal Doxorubicin Delivery in Pancreatic Cancer · Cancer Biotherapy and Radiopharmaceuticals · 2026 · Same journal
• Development of a Freeze-Dried Bevacizumab Kit for 99m Tc Radiolabeling and Preclinical Evaluation In Vitro and in Normal Mice · Cancer Biotherapy and Radiopharmaceuticals · 2026 · Same journal
• Radionuclide Therapy Integrated Multimodal Transsylvian Microneurosurgical Management of Type 5 Insular and Paralimbic Gliomas for Precision Oncology · Cancer Biotherapy and Radiopharmaceuticals · 2026 · Same journal
• Ultrasound-Potentiated Targeting of GLS1 by an Oridonin Derivative (R13) in Multiple Myeloma: Therapeutic Efficacy and Safety Considerations · Cancer Biotherapy and Radiopharmaceuticals · 2026 · Same journal
• Hemoglobin-Based Oxygen Carriers Promoted the Antitumor Effect of 177 Lu-PSMA-617 by Enhancing DNA Repair Capacity of Immune Cells · Cancer Biotherapy and Radiopharmaceuticals · 2026 · Same journal
• Prospective Clinical Assessment of Ultrasound-Assisted Radiopharmaceutical Imaging Under Anesthesia for Oncologic Evaluation · Cancer Biotherapy and Radiopharmaceuticals · 2026 · Same journal